Latest news with #Cerveny
Yahoo
a day ago
- General
- Yahoo
Colorado Confirms Multiple Wolf Pup Sightings
Wolf pups have been spotted in Pitkin County, Colorado, according to several sources, including a rancher whose calf was attacked by wolves this spring. Colorado Parks and Wildlife confirmed that it has seen pups in an emailed statement to Outdoor Life, and that their employees are continuing to monitor four den sites. 'CPW staff have begun to get minimum counts of pups by both direct observations and indirect methods,' the spokesperson wrote. 'It is important to note that sighting numbers (especially from early season sightings) are not a guaranteed number of animals since certainty in detection is low, based on continued denning, moving to rendezvous sites and being in varied habitat.' The agency declined to provide a specific pup count, and did not reply to a request for clarification on whether or how they're using trail cameras to monitor the pups. CPW also did not specify the county or counties of the den sites. But a Pitkin County rancher says at least some wolf pups are denning a quarter mile from his cows, according to the Colorado Sun, and that CPW officials are planning to use strategically placed roadkill to draw wolves away from his vulnerable new calves. One of the rancher's calves was attacked by a wolf over Memorial Day weekend, and he suspects the nearby pups are part of the Copper Creek Pack. On May 29 CPW officials euthanized a gray wolf from the Copper Creek Pack that had been chronically preying on livestock in Pitkin County. The Copper Creek Pack was trapped in the fall after multiple depredation incidents in another county, and ultimately released again in January. Fifteen wolves were captured in British Columbia and released in Pitkin and Eagle counties around the same time. The rancher, Mike Cerveny, is one of many stockgrowers frustrated by the way the reintroduction has threatened his livelihood. Cerveny told the Sun that he's not anti-wolf, 'just like I'm not an anti-crocodile or anti-hippo guy. Like, everything has its own area and place to be where they thrive. But do I think wolves should be dropped off in the freaking first week of January, when it's 20 below, next to my cows? Uh, no. I think this is the dumbest thing in the world.' While CPW has not yet released any formal statements about this year's pups, the agency has been publicizing its efforts to raise funding for non-lethal wolf mitigation through its speciality license program. On Tuesday the agency reported that selling some 18,000 'Born to Be Wild' vehicle license plates has raised almost $950,000 for conflict mitigation. Read Next: Colorado Officials Euthanize 'Chronic' Problem Wolf That Was Killing Livestock 'This special license plate allows Colorado residents to support ranchers by providing funding to CPW for non-lethal conflict minimization tools and programs and programs,' said CPW Director Jeff Davis. 'The hope is that this program will get the public engaged and increase overall sales of the license plate, in turn reducing impacts with livestock. These efforts help support the implementation of the state's Wolf Restoration and Management Plan and CPW's implementation of the state statute to restore a self-sustaining gray wolf population, all while supporting rural ways of life and the robust livestock industry that is such a critical component of Colorado's culture and economy.' Funds raised through the program include support for the state's range rider program, where riders on horseback or four-wheelers patrol livestock areas and haze wolves as necessary. In March, Colorado nearly drained its depredation compensation fund when it approved $343,000 in livestock losses.
Yahoo
06-06-2025
- Business
- Yahoo
Neural's Partner CWE to Open Store No. 16 in the City of Bonn and Invitation to Meet Hanf.com at Mary Jane Berlin 2025
Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as one of the Germany's leading CBD retailers, are pleased to provide an update on expansion efforts in Germany. A subsidiary of CWE has signed a franchise agreement to open the first in the City of Bonn-the former capital of The Federal Republic of Germany and home to over 320,000 residents. This marks fifth franchise agreement and the second store in the state of North Rhine-Westphalia. is also proud to announce its participation in Mary Jane Berlin 2025, Europe's premier cannabis trade show and festival, taking place June 19-22, 2025 at Messe Berlin. As part of the event's vibrant exhibition floor, will showcase its latest product innovations, including premium CBD oils, sustainable hemp-based wellness items, and exclusive new lifestyle offerings. Visitors can find at Booth #G19/G20, where they will be invited to explore, sample, and connect with the team behind one of the most trusted names in the hemp space. Alex Cerveny, COO of commented: "We are excited to bring the experience to Bonn-a city with deep roots and a progressive spirit. This new franchise marks an important step in our mission to make high-quality CBD products accessible to customers across Germany. We look forward to serving the Bonn community with the same passion, integrity, and innovation that defines the brand." "We are also thrilled to be part of Mary Jane Berlin again this year and invite our friends, partners, and associates to come meet our team." Mr. Cerveny added: "This event is not just a trade show-it's a celebration of cannabis culture, innovation, and progress. We look forward to engaging with industry partners and consumers to showcase our carefully curated portfolio of CBD products, as we continue paving the way for opening more franchise locations." Now in its ninth year, Mary Jane Berlin is expected to welcome over 60,000 visitors and more than 500 exhibitors from around the world. Programming includes expert panels, live music, food trucks, and a dedicated B2B business day. About Neural Therapeutics Neural Therapeutics is a leader in ethnobotanical drug discovery, focusing on the development of therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioid dependence. The Company's innovative approach to drug development involves the strategic use of sub-hallucinogenic doses of mescaline extract, enhancing safety and scalability while maintaining therapeutic efficacy. On May 26, 2025, Neural entered into a Strategic Investment and Option Agreement with CWE European Holdings Inc., a leading CBD hemp retailer in Germany operating under the brand to acquire up to 100% of CWE through a multi-stage transaction. The transaction is expected to expand Neural's commercial footprint in Europe while maintaining its core commitment to drug discovery and mental health innovation. For further inquiries, please contact:Neural Therapeutics Inc. Ian Campbell, CEOE: icampbell@ T: +1 (647) 697-NURL (6875) Marc LakmaakerE: mlakmaaker@ +1.647.289.6640 CAUTIONARY DISCLAIMER STATEMENT No securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of the contents of this news release. This news release contains forward-looking statements ("FLS") relating opening of new franchise locations by CWE (operating as the timing and scope of participation at Mary Jane Berlin 2025, the growth and performance of business, Neural's indirect exposure to such growth through its investment in CWE, and Neural's continued focus on ethnobotanical drug discovery. FLS may also include statements regarding potential synergies from the transaction between Neural and CWE, expected consumer reception of products and projections about European market demand for hemp and CBD-related goods. FLS are often identified by terms such as "will", "may", "should", "anticipate", "expect", "plan" and similar expressions. These statements are not statements of historical fact, but rather predictions about future events, which are inherently subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned should not to place undue reliance on any forward-looking information. Although management considers such information to be reasonable at the time of preparation, may prove to be incorrect and actual outcomes may differ significantly. FLS contained in this news release are expressly qualified by this cautionary statement. The Company expressly disclaims any intention or obligation to update or revise such statements. A description of additional risk factors that may cause actual results to differ materially from FLS in Neural's disclosure documents posted on The securities of Neural have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws. The securities may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons" (as defined in Regulation S under the U.S. Securities Act), unless registered or exempt from registration under the U.S. Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy Neural's securities in the United States or any other jurisdiction where such an offer or sale would be unlawful. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
06-06-2025
- Business
- Yahoo
Neural's Partner CWE to Open Store No. 16 in the City of Bonn and Invitation to Meet Hanf.com at Mary Jane Berlin 2025
Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as one of the Germany's leading CBD retailers, are pleased to provide an update on expansion efforts in Germany. A subsidiary of CWE has signed a franchise agreement to open the first in the City of Bonn-the former capital of The Federal Republic of Germany and home to over 320,000 residents. This marks fifth franchise agreement and the second store in the state of North Rhine-Westphalia. is also proud to announce its participation in Mary Jane Berlin 2025, Europe's premier cannabis trade show and festival, taking place June 19-22, 2025 at Messe Berlin. As part of the event's vibrant exhibition floor, will showcase its latest product innovations, including premium CBD oils, sustainable hemp-based wellness items, and exclusive new lifestyle offerings. Visitors can find at Booth #G19/G20, where they will be invited to explore, sample, and connect with the team behind one of the most trusted names in the hemp space. Alex Cerveny, COO of commented: "We are excited to bring the experience to Bonn-a city with deep roots and a progressive spirit. This new franchise marks an important step in our mission to make high-quality CBD products accessible to customers across Germany. We look forward to serving the Bonn community with the same passion, integrity, and innovation that defines the brand." "We are also thrilled to be part of Mary Jane Berlin again this year and invite our friends, partners, and associates to come meet our team." Mr. Cerveny added: "This event is not just a trade show-it's a celebration of cannabis culture, innovation, and progress. We look forward to engaging with industry partners and consumers to showcase our carefully curated portfolio of CBD products, as we continue paving the way for opening more franchise locations." Now in its ninth year, Mary Jane Berlin is expected to welcome over 60,000 visitors and more than 500 exhibitors from around the world. Programming includes expert panels, live music, food trucks, and a dedicated B2B business day. About Neural Therapeutics Neural Therapeutics is a leader in ethnobotanical drug discovery, focusing on the development of therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioid dependence. The Company's innovative approach to drug development involves the strategic use of sub-hallucinogenic doses of mescaline extract, enhancing safety and scalability while maintaining therapeutic efficacy. On May 26, 2025, Neural entered into a Strategic Investment and Option Agreement with CWE European Holdings Inc., a leading CBD hemp retailer in Germany operating under the brand to acquire up to 100% of CWE through a multi-stage transaction. The transaction is expected to expand Neural's commercial footprint in Europe while maintaining its core commitment to drug discovery and mental health innovation. For further inquiries, please contact:Neural Therapeutics Inc. Ian Campbell, CEOE: icampbell@ T: +1 (647) 697-NURL (6875) Marc LakmaakerE: mlakmaaker@ +1.647.289.6640 CAUTIONARY DISCLAIMER STATEMENT No securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of the contents of this news release. This news release contains forward-looking statements ("FLS") relating opening of new franchise locations by CWE (operating as the timing and scope of participation at Mary Jane Berlin 2025, the growth and performance of business, Neural's indirect exposure to such growth through its investment in CWE, and Neural's continued focus on ethnobotanical drug discovery. FLS may also include statements regarding potential synergies from the transaction between Neural and CWE, expected consumer reception of products and projections about European market demand for hemp and CBD-related goods. FLS are often identified by terms such as "will", "may", "should", "anticipate", "expect", "plan" and similar expressions. These statements are not statements of historical fact, but rather predictions about future events, which are inherently subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned should not to place undue reliance on any forward-looking information. Although management considers such information to be reasonable at the time of preparation, may prove to be incorrect and actual outcomes may differ significantly. FLS contained in this news release are expressly qualified by this cautionary statement. The Company expressly disclaims any intention or obligation to update or revise such statements. A description of additional risk factors that may cause actual results to differ materially from FLS in Neural's disclosure documents posted on The securities of Neural have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws. The securities may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons" (as defined in Regulation S under the U.S. Securities Act), unless registered or exempt from registration under the U.S. Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy Neural's securities in the United States or any other jurisdiction where such an offer or sale would be unlawful. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. To view the source version of this press release, please visit Sign in to access your portfolio
